Posted by Michael Wonder on 06 Oct 2023
Coherus announces resubmission of biologics license application supplement for Udenyca Onbody
5 October 2023 - Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler.
Coherus BioSciences today announced the Company has resubmitted the biologics license application supplement for Udenyca Onbody, the company's on-body injector presentation of Udenyca (pegfilgrastim-cbqv), to the US FDA for review.
